Cerulean’s siRNA-containing NDCs are designed to be taken up into tumor cells expressing green fluorescent protein (GFP), where they release their payload and decrease the expression of GFP. NDCs are shown in red and green intensity correlates with the level of GFP expression.
Cerulean’s clinically validated nanoparticle drug conjugates (NDCs) platform allows us to:
- Develop our own small molecule oncology products
- Potentially solve class limiting problems such as delivery of siRNA
- Develop products with partners by marrying their molecules, marketed or in development, with our platform
Learn more about CRLX101
Learn more about CRLX301
Learn more about Cerulean’s RNA Delivery Program